Justin I. Odegaard

Guardant (United States)

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index45

i10-index78

Publications251

Citations17,141

Grants

No NSF/NIH grants on record.

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0002

PageRank within Cancer Research co-authorship network

Explore collaboration map

Admission Signals

New paper: Abstract 3842: Non-invasive cfDNA methylation profiling for prediction of PD-L1 tumor proportion score status in NSCLC (Cancer Research)2026-04-03
New preprint: Supplementary Figure 1 from Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer2024-11-04

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0001-9957-2962

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 24

Abstract 3842: Non-invasive cfDNA methylation profiling for prediction of PD-L1 tumor proportion score status in NSCLC
Cancer Research · 2026-04-03
Abstract 100: Blood-based integration of epigenomic profiles, TMB, and MSI to predict immune checkpoint inhibitor response in advanced non-small cell lung cancer (aNSCLC).
Cancer Research · 2026-04-03
Abstract 1409: Fusion epigenotyping using cell-free DNA methylation improves detection of actionable ALK fusions in non-small cell lung cancer.
Cancer Research · 2026-04-03
Abstract 2279: DNA methylation-based classifier predicts SERD benefit in ESR1 wild-type HR+/HER2- breast cancer
Cancer Research · 2026-04-03
Abstract 107: An expanded negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA.
Cancer Research · 2026-04-03
Abstract 1012: Multi-omic method to detect MTAP homozygous deletions enables high sensitivity detection from blood samples
Cancer Research · 2026-04-03
Abstract 2584: Methylation signatures from liquid biopsies predict anti-EGFR therapy response in patients with colorectal cancer
Cancer Research · 2026-04-03
Application of an epigenomic-based classifier to identify cancer signal of origin on liquid biopsy in cancer of unknown primary cases.
Journal of Clinical Oncology · 2025-05-28
Analytic and clinical validation of a negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA.
Journal of Clinical Oncology · 2025-05-28
Abstract 5924: A Tumor-specific, methylation-based algorithm to identify MTAP gene deletions via tissue-free circulating tumor DNA
Cancer Research · 2025-04-21 · 1 citations
Abstract 3247: Liquid based methylation profiling for quantification of breast cancer subtypes
Cancer Research · 2025-04-21 · 1 citations
Abstract 733: Development and characterization of a negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA
Cancer Research · 2025-04-21
Abstract 1142: Non-invasive cell free DNA (cfDNA) methylation profiling for accurate proportional quantification of lung cancer subtypes
Cancer Research · 2025-04-21 · 1 citations
Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non–Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02
Journal of Molecular Diagnostics · 2025-01-27 · 7 citations
Supplementary Figure 1 from Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric CancerPreprint
2024-11-04
Supplementary Table 1 from Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
2024-11-04
Supplementary Table 2 from Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
2024-11-04
Supplementary Figure 3 from Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric CancerPreprint
2024-11-04
Supplementary Figure 2 from Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric CancerPreprint
2024-11-04
Supplementary Table 3 from Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
2024-11-04

Open author page on OpenAlex →